Advising AML patients to participate in clinical trials
Rigosertib in combination with azacitidine: a potential treatment for AML?
Checkpoint inhibitors in Hodgkin lymphoma
The future is bright for hematological oncology: promising areas for 2018 and beyond
Drug resistance in multiple myeloma: addressing the issue
Brian Van Ness